Emerging biotech companies are a significant and burgeoning sector of the pharmaceutical development market. These companies may require unique and specialized expertise to guide them through asset development. There are a multitude of considerations when evaluating an asset for development, including the vision for the asset, development and continuum capabilities, and global versus local development.
Download our latest whitepaper to learn:
- How to navigate the complexities of asset development
- Overall considerations emerging biotech companies can be discussing with development partners
- What makes a successful partner who can assist a small biotech company with necessary development strategies
This is the first in a series of white papers that will help outline considerations for asset development. Lead the pack in all steps of the development process with this guide.
5 Questions Small Biotech Should Ask Their Rare Disease Development Partner
Rare disease is a complicated but rewarding space for drug developers of all sizes. Most rare diseases have no approved treatment options, making…
Small Biotechnology Partnerships – A Success Story
PRA has experience partnering with small biotech firms, and we understand that they require a different approach than larger pharmaceutical…
Much More Than a Single Clinical Trial
Delivering drugs to the patients who need them can be an increasingly complex, time-consuming, and costly undertaking, particularly for smaller…